Palleon Pharmaceuticals
David Johnson was the Founder and CEO of VelosBio, which was acquired by Merck in 2020. Prior to this, Mr. Johnson was the CEO of Acerta Pharma, up until its acquisition by AstraZeneca. He has served in various roles at Hoffmann-La Roche, Immunex (acquired by Amgen), Millennium (acquired by Takeda), Favrille, Gloucester (acquired by Celgene), and Calistoga (acquired by Gilead).
This person is not in the org chart
This person is not in any offices
Palleon Pharmaceuticals
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer.